In Short This phase Ib/II study evaluated the efficacy and safety of Lenvima combined with Halaven in the treatment of patients with advanced leiomyosarcoma and liposarcoma. The results showed that…
Background about Glioblastoma and the new drug Glioblastoma (GBM) has a poor prognosis, and patients with Epidermal Growth Factor Receptor (EGFR) amplification have an even worse prognosis. Nimotuzumab is an…
The Rational for Vitamin C in Colorectal Cancer The use of vitamin C in cancer treatment can be traced to more than 40 years ago. Back then two retrospective studies…
Background In this randomized clinical trial that included 585 patients with extensive-stage Small Cell Lung Cancer, SCLC, who had not previously received systemic therapy, Seplulimab plus chemotherapy, compared with Placebo…
Background A significant period until disease progression was seen in patients with metastatic renal cell cancer (RCC) receiving the triplet combination of Cometriq plus Yervoy and Opdivo, according to a…
BACKGROUND Cisplatin-based combination chemotherapy remains the standard of care for locally advanced or metastatic bladder cancer. However, toxicity is substantial, responses are rarely durable, and many locally advanced or metastatic…
Background Lurbinectedin, a selective inhibitor of oncogenic transcription, has shown preclinical antitumor activity against homologous recombination repair-deficient (HRD) models and preliminary clinical activity in BRCA1/2 breast cancer. Introduction Breast cancer…
Background - Glioblastoma and CV-01 Glioblastoma is a diffuse, infiltrative disease with tumor cells invading far beyond the borders of the visible tumor. The diffuse nature of Glioblastomas, often across…
Background Among women, ovarian cancer is the 5th most common type of cancer. The risk of getting this cancer in one lifetime is 1 in 78. Treatment with Apatinib plus…
Background The antibody-drug conjugate Trodelvy offers statistically and clinically significant benefits for patients with heavily pretreated HR+/HER2- breast cancer, according to results of the TROPiCS-02 study, recently presented. HR+/HER2- is…